welcome to oneGRAVESvoice- a positively charged Graves' disease and thyroid eye disease community.
- join today!
- log in
The New England Journal of Medicine Publishes Comprehensive Data From Phase 3 Clinical Trial (OPTIC) of TEPEZZA™ (Teprotumumab-Trbw) for Thyroid Eye Disease
Horizon Therapeutics plc announced that The New England Journal of Medicine has published comprehensive results of the Phase 3 OPTIC clinical trial evaluating TEPEZZA™ (teprotumumab-trbw) for Thyroid Eye Disease (TED). OPTIC is part of the largest clinical program in TED and demonstrates that TEPEZZA provides significant improvements in proptosis (eye bulging) and diplopia (double vision) compared to placebo.
TEPEZZA is a fully human monoclonal antibody (mAb) and a targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R) that is administered to patients once every three weeks for a total of eight infusions. TEPEZZA was approved by the U.S. Food and Drug Administration (FDA) on January 21, 2020 – making it the first and only medicine approved for the treatment of TED. The medicine received Priority Review, Orphan Drug, Fast Track and Breakthrough Therapy designations from the FDA.
More from Teprotumumab News:
More from Teprotumumab Research:
(Author: Raymond S. Douglas)
Charles Sydnor, MDCharles Sydnor began his private ophthal...
Teprotumumab for the Treatment of Active Thyroid Eye DiseaseBackground: Thyroid eye disease is a de...
“TED Today” Episode 1https://www.facebook.com/ThyroidEyes/vid...
TEPEZZA Has Resumed Production – FAQHorizon Therapeutics, the developer of T...
Stanford Doctor Discusses Thyroid Eye Disease: Understanding the Disease and New Treatmentshttps://www.youtube.com/watch?v=clBkmWQi...
Wills Eye HospitalWills Eye Hospital, located in Philadelp...
Preoperative Clinical Features of Reactivated of Graves’ Orbitopathy After Orbital DecompressionPurpose: To investigate the incidence a...